Latest Small interfering RNA Stories
LONDON, September 18, 2012 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN), a leading global RNA interference (RNAi) therapeutics company, today announces the appointment of Michael Khan to its board of directors as Chief Medical Adviser. Dr Michael Khan BSc, MBBS, PhD, FRCP is an Associate Professor of Medicine at the University of Warwick and a Consultant Physician at University Hospitals. He trained in medicine at Guy's and King's in London and completed...
LONDON, September 10, 2012 /PRNewswire/ -- Silence Therapeutics plc [http://silence-therapeutics.com ] (AIM: SLN) ("Silence" or "the Company"), a leading RNA [http://silence-therapeutics.com/content/therapeuticplatform/overview.htm ] interference (RNAi) therapeutics company is pleased to announce that recent data in pre-clinical models demonstrated the efficacy of Atu111 in acute lung injury. Atu111 targets the endothelial expression of Angiopoietin-2 (Ang-2), an antagonistic...
CARLSBAD, Calif., Aug. 30, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today the publication of two papers in the journal Cell demonstrating that single-stranded short interfering RNA (ss-siRNA) molecules distributed broadly, activated the RNA interference (RNAi) pathway and reduced expression of targeted genes in animal models. The RNAi pathway is a mechanism that can be used to inhibit expression of genes. The RNAi pathway has typically been engaged by...
LONDON, August 2, 2012 /PRNewswire/ -- Silence Therapeutics plc [http://silence-therapeutics.com ] (AIM: SLN) ("Silence" or "the Company"), a leading RNA [http://silence-therapeutics.com/content/therapeuticplatform/overview.htm ] interference (RNAi) therapeutics company, announces that the New Shares issued in connection with the Subscription, Open Offer and Convertible Loan Note have today been admitted to trading on AIM. In addition, as set out in the Circular to...
SANTA CRUZ, Calif., July 24, 2012 /PRNewswire/ -- SomaGenics, Inc., a biotechnology company specializing in RNA-based technologies, announced the publication of a study reporting the mechanism of action of its sshRNAs, the class of molecules that forms the basis of the company's therapeutic platform. sshRNAs are small synthetic stem-loop (or hairpin) RNAs that the company's researchers have shown to be highly potent in knocking down target RNAs through an RNA interference (RNAi)...
Steve Moose, an associate professor of maize functional genomics at the University of Illinois and his graduate student Wes Barber think they may have discovered a new source of heterosis, or hybrid vigor, in maize. They have been looking at small RNAs (sRNAs), a class of double-stranded RNA molecules that are 20 to 25 nucleotides in length. “Hybrid vigor” refers to the increased vigor or general health, resistance to disease, and other superior qualities arising from the crossbreeding...
GAITHERSBURG, Md., June 25, 2012 /PRNewswire/ -- Sirnaomics, Inc. (www.sirnaomics.com) announced today that the company has been awarded another NIH SBIR (Small Business Innovation Research) grant for developing its small interfering RNA (siRNA) therapeutic product STP705 to improve skin wound healing with minimized scar formation. This funding will further enhance the company's effort for perfection of its nanoparticle-based siRNA delivery systems and speed up the IND enabling...
LONDON, June 6, 2012 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company"), a leading global RNA interference [http://silence-therapeutics.com/platform-technologies/rna-interference ] (RNAi) therapeutics company, on Monday presented the latest data from its ongoing Phase I study of Atu027, its lead internal therapeutics candidate, alongside the 2012 American Society of Clinical Oncology ("ASCO") Annual Meeting in Chicago, Illinois. At...
LONDON, May 17, 2012 /PRNewswire/ -- - Atu027, a First in Class RNAi Therapy, Demonstrates Potential - Antitumour Activity in Cancer Patients and Possible Biomarker Identified Silence Therapeutics to Announce New Data from Phase I Study of Atu027 in Solid Tumours At 2012 ASCO Annual Meeting Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company"), a leading global RNA interference (RNAi) therapeutics...
FARMINGTON, Conn., May 14, 2012 /PRNewswire-iReach/ -- Global Information Inc. is pleased to announce two significant new reports on RNA interference (RNAi) and its relationship with peripheral markets: RNA Interference (RNAi) Global Industry Analysts' new RNA Interference (RNAi) market research report provides annual estimates and forecasts for drug discovery and target validation, reagents, and siRNA synthesis. This report analyzes the worldwide markets for RNA Interference (RNAi)...
